NK4 (Kringle Pharma)

N/A

Report date: 2025/03/20 15:45:49

Base Information

Drug NameNK4 (Kringle Pharma)

Drug Alias NameHGF antagonist (Osaka University)HGF antagonist (Osaka University/Kringle Pharma)NK4 (Osaka University)NK4 HGF antagonist (Osaka University/Kringle)NK4

ClassificationBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionHepatocyte growth factor receptor inhibitors

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOsaka University

China Registration ClassN/A

Develop Information

Active CompaniesKringle Pharma Inc

Inactive CompaniesOsaka University

Active IndicationsSolid tumours

Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A